Amgen cuts 'several hundred' U.S. jobs, primarily sales reps, as COVID-19 speeds a shift to digital Data privacy startup SkyFlow jumps into digital health passport market to help public spaces reopen GSK inks deal to produce CureVac's COVID-19 vaccine—and develop a next-gen version, too Pfizer, Johnson & Johnson balk at shareholders' push for COVID-19 vaccine pricing info Humana posts $274M profit loss in Q4, cites significant increase in COVID-19 costs BD secures European approval for COVID-19 blood test to predict which patients may need a ventilator Bristol Myers makes late play for COVID-19 antibody space, picking up 2 early-phase molecules from Rockefeller COVID-19 tracker: Novavax shot starts rolling review in Europe; Bristol Myers joins the COVID antibody fray UPDATED Coronavirus tracker: FEMA to deliver $1.7B to localities for vaccine distribution As GSK enters key transition year, COVID-19 immunization could hurt Shingrix uptake: exec Featured Story | By Beth Snyder Bulik Amgen is cutting "several hundred" jobs, and its U.S. sales teams are bearing the brunt of it. The California-based drugmaker confirmed Wednesday that it is shrinking its workforce, "primarily in the U.S. sales force," as it pivots to upcoming drug launches and adopts pandemic-time digital marketing tools for the long run. read more |
| |
|---|
|
| | Webinar: The Benefits of Pharmacist-Led Clinical Trials Tuesday, February 23, 2021 | 1pm ET / 10am PT This webinar will focus on how a pharmacist-led clinical trial model impacts the six key areas most relevant to clinical trials in today’s COVID and Decentralized Clinical Trial environment: regulations, recruiting, diversity, clinical outcomes, data integrity, and clinical supply chain. Register Now. |
Top Stories By Brian T. Horowitz Startup SkyFlow is entering the health care space to provide a way for people to go back to public spaces amid the COVID-19 pandemic with a digital passport. SkyFlow investor Jonathan Bush says the company is taking a unique "privacy-first" approach to ease the sharing of COVID-19 test results and vaccination data. read more By Angus Liu As a Sanofi-partnered vaccine falls behind in the COVID-19 race, GlaxoSmithKline has decided to team with CureVac to help manufacture its current phase 3 mRNA candidate and develop a multivalent shot to tackle emerging variants of the novel coronavirus. It's a chance to move to a "next-gen solution," GSK CEO Emma Walmsley said. read more By Kevin Dunleavy What's the rationale behind COVID-19 vaccine and drug prices when federal funding is involved? Some investors want to know—and they've asked a half-dozen companies to put the idea to a shareholder vote—but a couple of the leading contenders are fighting back. read more By Paige Minemyer Humana is intending to grow its newly launched Author model, which takes a tech-enabled approach to personalized care. read more By Conor Hale BD has launched a new COVID-19 blood test in Europe that can help hospitals identify incoming patients that may be more likely to require intensive care with a ventilator and carry a higher risk of death from the disease. read more By Nick Paul Taylor Bristol Myers Squibb has secured global rights to a pair of anti-SARS-CoV-2 antibodies discovered by The Rockefeller University. The antibodies entered phase 1 development last month, putting them well behind similar therapies from companies including Eli Lilly and Regeneron. read more By Fraiser Kansteiner,Eric Sagonowsky,Angus Liu,Conor Hale Novavax's shot is now part of a rolling review in Europe. Meanwhile, Switzerland declined to authorize AstraZeneca's vaccine. Bristol Myers picked up the rights to a pair of antibodies discovered by The Rockefeller University. Biogen's Spinraza and GSK's Shingrix took pandemic sales hits. And BD rolled out a new blood test in Europe. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Angus Liu Shingles vaccine Shingrix has been GlaxoSmithKline’s major growth driver. But during the pandemic, even it couldn’t draw on its full strength. In addition to the pandemic hurting doctors' visits, the new COVID immunization campaign could also drag down uptake in 2021, the company said. read more |
